Endogenex said the study "demonstrates substantial and durable reduction in insulin resistance and improvement in beta cell ...

Aktiia announced today that it raised an oversubscribed $42 million Series B funding round and introduced its new "Hilo" ...

Inquis Medical today announced findings from the AVENTUS trial evaluating the safety and efficacy of its Aventus thrombectomy ...

ElectroCore (Nasdaq:ECOR) announced today that it completed its previously announced acquisition of NeuroMetrix  (Nasdaq:NURO ...

Baxter EVP and CFO Joel Grade said some tariff mitigation activities are underway while others are being developed.

The company reports that NUOS 3 can enable patients who have been declared clinically dead — at times for over 30 minutes — and later resuscitated to regain the ability to communicate. Despite ...